3Steinshamn S, Sandsund M, Sue-Chu M, et al. Effects of montelukast on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction[J]. Scand J Med Sci Sports , 2002, 12(4):211-217.
4Niewoehner DE. Montelukast improved pulmonary function and asthma-specific quality of life in aspirin-intolerant asthma[J]. ACP J Club, 2002, 137(1):20.
5Zhang J, Yu C, Noonan G, et al. Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability[J]. Clin Ther, 2002, 24(4):574-582.
6Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresportsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor ( sIL-2R), IL-4, and soluble intercellular adhesion molecule 1(sICAM-1) in children with asthma[J]. J Allergy Clin Immunol, 2002, 109(2) :257 - 263.
7Dempsey O J, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukolriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma [ J ]. J Allergy Clin Immunol, 2002, 109(1):68-74.
8Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA, et al.The efficacy of montelukast in the treatment of cat allergen-induced asthma in children[J]. J Allergy Clin Immunol,2002, 109(5) :794 - 799.
9Henderson WR Jr, Tang LO, Chu SJ, at al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model[J]. Am J Respir Crit Care Med, 2002, 165(1):108- 116.
10Fregonese L, Silvestri M, Sabatini F, et al. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism[J]. Clin Exp Allergy, 2002, 32(5):745 -750.
9Kony S,Zureik M,Driss F, et aI.Association of bronchial hyperresponsiveness and lung function with C-reactive protein.(CRP):a population based study[J]. Thorax,2004 Oct;59( 10):892-896.
